Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay

An enzyme-linked immunosorbent assay (ELISA) using monoclonal and polyclonal antibodies against t-PA was used to measure the concentration of tissue-type plasminogen activator (t-PA) in plasma from 34 healthy donors and 92 breast cancer patients with a varying extent of disease. The mean value of t-...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1990-03, Vol.61 (3), p.412-414
Main Authors: Grøndahl-Hansen, J, Bach, F, Munkholm-Larsen, P
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - blood
Cancer Research
Drug Resistance
Enzyme-Linked Immunosorbent Assay
Epidemiology
experimental-oncology
Female
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Molecular Medicine
Oncology
Tissue Plasminogen Activator - blood
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An enzyme-linked immunosorbent assay (ELISA) using monoclonal and polyclonal antibodies against t-PA was used to measure the concentration of tissue-type plasminogen activator (t-PA) in plasma from 34 healthy donors and 92 breast cancer patients with a varying extent of disease. The mean value of t-PA in plasma for the healthy donors was 2.4 +/- 2.1 ng ml-1 (s.d.). The mean value for the breast cancer patients was 5.3 +/- 4.3 ng ml-1. This increase was statistically significant at the 1% level. There was a positive correlation between the mean t-PA plasma concentration and the extent of disease in different groups of patients. Taking 5.0 ng ml-1 as cut-off point, about 40% of the patients were positive, and 6% of the normal controls were false positive. Twenty-five per cent of the patients in complete remission, 28% of the patients with minimal tumour burden, 60% of the patients with moderate tumour burden, and 90% of the patients with massive tumour burden were positive. It is possible that the patients with an elevated plasma t-PA represent a group with a particularly bad prognosis.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1990.90